Literature DB >> 35658014

ILC2s-Bipartisan politicians in cancer.

Abderezak Zebboudj1,2, Masataka Amisaki1,2, Vinod P Balachandran1,2,3,4.   

Abstract

Group 2 innate lymphoid cells (ILC2s) are lymphocytes that both promote and suppress antitumor immunity. Jou and colleagues now report in colorectal tumorigenesis that the cytokine interleukin-25 activates ILC2s to induce myeloid cells that suppress antitumor immunity.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35658014      PMCID： PMC9207974          DOI： 10.1126/sciimmunol.abq2791

Source DB:  PubMed          Journal:  Sci Immunol        ISSN： 2470-9468


  10 in total

1.  ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.

Authors:  Joanne Leung; Luis A Rojas; Jennifer Ruan; John Alec Moral; Julia Zhao; Zachary Sethna; Anita Ramnarain; Billel Gasmi; Murali Gururajan; David Redmond; Gokce Askan; Umesh Bhanot; Ela Elyada; Youngkyu Park; David A Tuveson; Mithat Gönen; Steven D Leach; Jedd D Wolchok; Ronald P DeMatteo; Taha Merghoub; Vinod P Balachandran
Journal:  Nature       Date:  2020-02-19       Impact factor: 49.962

2.  Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity.

Authors:  Masashi Ikutani; Tsutomu Yanagibashi; Masaru Ogasawara; Koichi Tsuneyama; Seiji Yamamoto; Yuichi Hattori; Taku Kouro; Atsuko Itakura; Yoshinori Nagai; Satoshi Takaki; Kiyoshi Takatsu
Journal:  J Immunol       Date:  2011-12-14       Impact factor: 5.422

3.  An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for Apc mutation-driven intestinal tumorigenesis.

Authors:  Eric Jou; Noe Rodriguez-Rodriguez; Ana-Carolina F Ferreira; Helen E Jolin; Paula A Clark; Kovilen Sawmynaden; Michelle Ko; Jane E Murphy; Jonathan Mannion; Christopher Ward; David J Matthews; Simon J A Buczacki; Andrew N J McKenzie
Journal:  Sci Immunol       Date:  2022-06-03

4.  PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma.

Authors:  Emily Howard; Benjamin P Hurrell; Doumet Georges Helou; Christine Quach; Jacob D Painter; Pedram Shafiei-Jahani; Marshall Fung; Parkash S Gill; Pejman Soroosh; Arlene H Sharpe; Omid Akbari
Journal:  Front Immunol       Date:  2021-08-31       Impact factor: 8.786

5.  Intratumorally Establishing Type 2 Innate Lymphoid Cells Blocks Tumor Growth.

Authors:  Juyang Kim; Wonyoung Kim; U J Moon; Hyun J Kim; Hye-Jeong Choi; Jeong-Im Sin; Neung H Park; Hong R Cho; Byungsuk Kwon
Journal:  J Immunol       Date:  2016-02-01       Impact factor: 5.422

6.  Type 2 Innate Lymphocytes Actuate Immunity Against Tumours and Limit Cancer Metastasis.

Authors:  Iryna Saranchova; Jeffrey Han; Rysa Zaman; Hitesh Arora; Hui Huang; Franz Fenninger; Kyung Bok Choi; Lonna Munro; Cheryl G Pfeifer; Ian Welch; Fumio Takei; Wilfred A Jefferies
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

7.  ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung.

Authors:  Martijn J Schuijs; Shaun Png; Arianne C Richard; Anastasia Tsyben; Gregory Hamm; Julie Stockis; Celine Garcia; Silvain Pinaud; Ashley Nicholls; Xavier Romero Ros; Jing Su; Matthew D Eldridge; Angela Riedel; Eva M Serrao; Hans-Reimer Rodewald; Matthias Mack; Jacqueline D Shields; E Suzanne Cohen; Andrew N J McKenzie; Richard J A Goodwin; Kevin M Brindle; John C Marioni; Timotheus Y F Halim
Journal:  Nat Immunol       Date:  2020-08-03       Impact factor: 25.606

8.  Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.

Authors:  Sara Trabanelli; Mathieu F Chevalier; Amaia Martinez-Usatorre; Alejandra Gomez-Cadena; Bérengère Salomé; Mariangela Lecciso; Valentina Salvestrini; Grégory Verdeil; Julien Racle; Cristina Papayannidis; Hideaki Morita; Irene Pizzitola; Camille Grandclément; Perrine Bohner; Elena Bruni; Mukul Girotra; Rani Pallavi; Paolo Falvo; Elisabeth Oppliger Leibundgut; Gabriela M Baerlocher; Carmelo Carlo-Stella; Daniela Taurino; Armando Santoro; Orietta Spinelli; Alessandro Rambaldi; Emanuela Giarin; Giuseppe Basso; Cristina Tresoldi; Fabio Ciceri; David Gfeller; Cezmi A Akdis; Luca Mazzarella; Saverio Minucci; Pier Giuseppe Pelicci; Emanuela Marcenaro; Andrew N J McKenzie; Dominique Vanhecke; George Coukos; Domenico Mavilio; Antonio Curti; Laurent Derré; Camilla Jandus
Journal:  Nat Commun       Date:  2017-09-19       Impact factor: 14.919

9.  Tissue signals imprint ILC2 identity with anticipatory function.

Authors:  Roberto R Ricardo-Gonzalez; Steven J Van Dyken; Christoph Schneider; Jinwoo Lee; Jesse C Nussbaum; Hong-Erh Liang; Dedeepya Vaka; Walter L Eckalbar; Ari B Molofsky; David J Erle; Richard M Locksley
Journal:  Nat Immunol       Date:  2018-09-10       Impact factor: 25.606

10.  Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma.

Authors:  Angela Pizzolla; Yang Liao; Soroor Hediyeh-Zadeh; Melissa J Davis; Wei Shi; Paul J Neeson; Nicolas Jacquelot; Cyril Seillet; Minyu Wang; Sharon Grisaru-Tal; Cynthia Louis; Qiutong Huang; Jaring Schreuder; Fernando Souza-Fonseca-Guimaraes; Carolyn A de Graaf; Kevin Thia; Sean Macdonald; Mary Camilleri; Kylie Luong; Shengbo Zhang; Michael Chopin; Tristan Molden-Hauer; Stephen L Nutt; Viktor Umansky; Bogoljub Ciric; Joanna R Groom; Paul S Foster; Philip M Hansbro; Andrew N J McKenzie; Daniel H D Gray; Andreas Behren; Jonathan Cebon; Eric Vivier; Ian P Wicks; Joseph A Trapani; Ariel Munitz; Gabrielle T Belz
Journal:  Nat Immunol       Date:  2021-06-07       Impact factor: 25.606
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.